It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...

CAPEX investment for setting up the PERC production is higher in the case of a MLD setup. Image: Fraunhofer ISE A solar cell manufacturing plant can reduce water consumption by up to 79% with existing ...

Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--LumaCyte, a leader in advanced cellular analysis and precision bioanalytics, proudly announces the launch of its groundbreaking cell therapy application for ...

DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...